Skip to content
Inciteful Med

The Biology of Vision: How Rods, Cones, and Genes Work Together

Last updated:

Retinitis Pigmentosa (RP) is driven by genetic mutations that first destroy rod cells, causing night blindness, and eventually starve cone cells, affecting central vision. Knowing your specific gene mutation is essential for understanding your disease progression and finding targeted treatments.

Key Takeaways

  • • Retinitis pigmentosa typically starts by affecting rod cells, which causes night blindness and the loss of peripheral vision.
  • • The eventual loss of central vision occurs because dying rods can no longer produce essential support proteins that keep cone cells alive.
  • • Inheritance patterns like X-Linked, Autosomal Recessive, and Autosomal Dominant provide important clues about the typical severity and progression speed of the disease.
  • • Identifying your exact genetic mutation is crucial for determining your eligibility for targeted clinical trials and approved gene therapies.

Retinitis Pigmentosa (RP) is a genetic condition that rewrites the “instruction manual” for the cells in your eyes. To understand how the disease works, it helps to view the eye as a biological machine where many different parts must work in perfect harmony. When one part—a specific gene—has a typo, it can disrupt the entire system [1].

The Two Main Players: Rods and Cones

As introduced during your initial diagnosis, your retina contains two primary types of light-sensing cells called photoreceptors. They have very different jobs:

  • Rods (The Night Crew): These cells are highly sensitive to light. They allow you to see in the dark and manage your peripheral (side) vision. In most forms of RP, rods are the first to be affected, which is why night blindness is almost always the very first symptom [2].
  • Cones (The Detail Team): These cells are responsible for sharp central vision and seeing color. They work best in bright light. While RP usually starts in the rods, the cones eventually become involved, which is why central vision typically remains clear until later stages of the disease [3].

The Biological “Bystander Effect”

You might wonder: if a genetic typo only affects the rods, why do the cones eventually die too? Scientists call this secondary loss of cones a “non-cell-autonomous” degeneration [3].
Essentially, rods provide more than just vision; they also produce a “support protein” called Rod-derived Cone Viability Factor (RdCVF). Think of this protein as “food” for the cones. When the rods die off, the cones lose their primary food source and begin to starve [4][5]. Additionally, the loss of rods causes an “oxygen overload” in the eye (hyperoxia), which creates toxic molecules called reactive oxygen species that further damage the remaining cone cells [6][7].

Decoding Your Genetic Results

Your genetic report will likely mention an inheritance pattern, which describes how the condition was passed down through your family. This pattern often gives doctors a clue about the likely “speed” of the disease:

Inheritance Pattern Common Genes Typical Severity
X-Linked (XLRP) RPGR, RP2 Often the most severe; symptoms often begin in early childhood [8][9].
Autosomal Recessive USH2A, EYS, RPE65 Highly variable; can range from severe to more moderate progression [10][11].
Autosomal Dominant RHO, RP1 Often a milder course with a later age of onset [12][13].

Key Genes to Know

  • RPGR: The most common cause of X-linked RP. It is responsible for transporting vital proteins within the photoreceptor cells [14].
  • USH2A: Often associated with Usher Syndrome, which includes both RP and hearing loss [15].
  • EYS: A common cause of recessive RP, often leading to symptoms in the late teens or early twenties [16].
  • RPE65: This gene is unique because it is one of the few with an FDA-approved gene therapy. It is involved in the “visual cycle”—the process of recycling chemicals the eye needs to see light [17].

Understanding your specific gene is the first step toward finding potential clinical trials or therapies that are targeted specifically to your biological needs [18].

Frequently Asked Questions

Why does retinitis pigmentosa cause night blindness first?
In most forms of RP, the disease first attacks rod cells in your retina. Because rods are the cells responsible for seeing in the dark and managing your peripheral vision, night blindness is almost always the earliest symptom you will notice.
How does the loss of rod cells affect my central vision and cone cells?
Rod cells produce a support protein that essentially acts as food for your cone cells. When rods die off, the cones lose their primary food source and are exposed to toxic oxygen levels, causing them to eventually degenerate and affect your central vision.
What do inheritance patterns like X-linked or autosomal dominant mean for my RP?
Inheritance patterns describe how the genetic mutation was passed down through your family. This pattern gives doctors important clues about the likely severity and speed of your disease progression, helping them predict how your vision may change over time.
Why is it important to know my specific gene mutation?
Knowing your exact genetic mutation, such as RPGR, USH2A, or RPE65, is the crucial first step toward finding treatments. It helps determine your eligibility for specific clinical trials and FDA-approved gene therapies tailored to your biological needs.
What is the RPE65 gene and why is it important?
The RPE65 gene is involved in the visual cycle, which is how your eye recycles the chemicals needed to see light. It is especially notable because it is one of the few genetic mutations in RP that currently has an FDA-approved gene therapy.

Questions for Your Doctor

  • • Which inheritance pattern was identified in my genetic report, and what does that mean for my children?
  • • Is my specific mutation in the RPGR gene located in the 'ORF15' region, and does that affect my eligibility for current gene therapy trials?
  • • Based on my genetic result (e.g., USH2A or EYS), what is the typical 'window' for preserving central vision?

Questions for You

  • • Does your genetic report mention 'Variants of Uncertain Significance' (VUS), or were the findings clear and definitive?
  • • Have you noticed changes in how you see colors or the sharpness of objects directly in front of you, which might signal that your cone cells are being affected?
  • • Are you interested in participating in a patient registry (like My Retina Tracker) to stay informed about research specific to your gene?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Gene panel sequencing in Brazilian patients with retinitis pigmentosa.

    Costa KA, Salles MV, Whitebirch C, et al.

    International journal of retina and vitreous 2017; (3()):33 doi:10.1186/s40942-017-0087-6.

    PMID: 28912962
  2. 2

    Metabolic rescue of cone photoreceptors in retinitis pigmentosa.

    Kaplan HJ, Wang W, Piri N, Dean DC

    Taiwan journal of ophthalmology 2021; (11(4)):331-335 doi:10.4103/tjo.tjo_46_21.

    PMID: 35070660
  3. 3

    Mechanism of Cone Degeneration in Retinitis Pigmentosa.

    Song DJ, Bao XL, Fan B, Li GY

    Cellular and molecular neurobiology 2023; (43(3)):1037-1048 doi:10.1007/s10571-022-01243-2.

    PMID: 35792991
  4. 4

    Combined Expression of hRdCVF and hRdCVFL Through AAV-Mediated Delivery for the Treatment of Retinitis Pigmentosa.

    Clérin E, Yang Y, Pagan D, et al.

    Investigative ophthalmology & visual science 2026; (67(3)):2 doi:10.1167/iovs.67.3.2.

    PMID: 41769936
  5. 5

    Restoration of Rod-Derived Metabolic and Redox Signaling to Prevent Blindness.

    Clérin E, Aït-Ali N, Sahel JA, Léveillard T

    Cold Spring Harbor perspectives in medicine 2024; (14(11)) doi:10.1101/cshperspect.a041284.

    PMID: 37848252
  6. 6

    Reduced inspired oxygen decreases retinal superoxide radicals and promotes cone function and survival in a model of retinitis pigmentosa.

    Kanan Y, Hackett SF, Hsueh HT, et al.

    Free radical biology & medicine 2023; (198()):118-122 doi:10.1016/j.freeradbiomed.2023.01.021.

    PMID: 36736930
  7. 7

    Retinitis Pigmentosa (RP): The Role of Oxidative Stress in the Degenerative Process Progression.

    Vingolo EM, Casillo L, Contento L, et al.

    Biomedicines 2022; (10(3)) doi:10.3390/biomedicines10030582.

    PMID: 35327384
  8. 8

    RPGR-Related Retinopathy: Clinical Features, Molecular Genetics, and Gene Replacement Therapy.

    Awadh Hashem S, Georgiou M, Ali RR, Michaelides M

    Cold Spring Harbor perspectives in medicine 2023; (13(11)) doi:10.1101/cshperspect.a041280.

    PMID: 37188525
  9. 9

    Novel mutations of RPGR in Chinese families with X-linked retinitis pigmentosa.

    Zhang Z, Dai H, Wang L, et al.

    BMC ophthalmology 2019; (19(1)):240 doi:10.1186/s12886-019-1250-7.

    PMID: 31775781
  10. 10

    Novel Heterozygous Deletion in Retinol Dehydrogenase 12 (RDH12) Causes Familial Autosomal Dominant Retinitis Pigmentosa.

    Sarkar H, Dubis AM, Downes S, Moosajee M

    Frontiers in genetics 2020; (11()):335 doi:10.3389/fgene.2020.00335.

    PMID: 32322264
  11. 11

    CNGB1-related rod-cone dystrophy: A mutation review and update.

    Nassisi M, Smirnov VM, Solis Hernandez C, et al.

    Human mutation 2021; (42(6)):641-666 doi:10.1002/humu.24205.

    PMID: 33847019
  12. 12

    The Location of Exon 4 Mutations in RP1 Raises Challenges for Genetic Counseling and Gene Therapy.

    Nanda A, McClements ME, Clouston P, et al.

    American journal of ophthalmology 2019; (202()):23-29 doi:10.1016/j.ajo.2019.01.027.

    PMID: 30731082
  13. 13

    New COL6A6 Variant Causes Autosomal Dominant Retinitis Pigmentosa in a Four-Generation Family.

    Vaclavik V, Tiab L, Sun YJ, et al.

    Investigative ophthalmology & visual science 2022; (63(3)):23 doi:10.1167/iovs.63.3.23.

    PMID: 35333290
  14. 14

    Gelsolin dysfunction causes photoreceptor loss in induced pluripotent cell and animal retinitis pigmentosa models.

    Megaw R, Abu-Arafeh H, Jungnickel M, et al.

    Nature communications 2017; (8(1)):271 doi:10.1038/s41467-017-00111-8.

    PMID: 28814713
  15. 15

    Ciliopathy: Usher Syndrome.

    Tsang SH, Aycinena ARP, Sharma T

    Advances in experimental medicine and biology 2018; (1085()):167-170 doi:10.1007/978-3-319-95046-4_32.

    PMID: 30578505
  16. 16

    Clinical characteristics of EYS-associated retinal dystrophy in 291 Japanese patients.

    Koyanagi Y, Murakami Y, Kominami T, et al.

    NPJ genomic medicine 2025; (11(1)):3 doi:10.1038/s41525-025-00541-0.

    PMID: 41353252
  17. 17

    Successful arrest of photoreceptor and vision loss expands the therapeutic window of retinal gene therapy to later stages of disease.

    Beltran WA, Cideciyan AV, Iwabe S, et al.

    Proceedings of the National Academy of Sciences of the United States of America 2015; (112(43)):E5844-53 doi:10.1073/pnas.1509914112.

    PMID: 26460017
  18. 18

    USH2A variants causing retinitis pigmentosa or Usher syndrome provoke differential retinal phenotypes in disease-specific organoids.

    Sanjurjo-Soriano C, Jimenez-Medina C, Erkilic N, et al.

    HGG advances 2023; (4(4)):100229 doi:10.1016/j.xhgg.2023.100229.

    PMID: 37654703

This page provides educational information about the biology and genetics of Retinitis Pigmentosa. It is not intended as medical advice; always consult your ophthalmologist or genetic counselor about your specific genetic report and diagnosis.

Stay up to date

Get notified when new research about Retinitis pigmentosa is published.

No spam. Unsubscribe anytime.